.png)
Future Surgery
Anaesthesia & Critical Care
Cardiovascular Professional Care
Time: 10.00-10.45, 11.00-11.45, 12.00-12.45
This promotional workshop will provide a practical guide on the use of Ondexxya®▼(andexanet alfa) to support the acute management of patients on apixaban or rivaroxaban who present with a life-threatening bleed. The session will include an overview on the dosing and administration of the product as well as guidance on storage and integrating the use of Ondexxya within pathways.
This is a promotional workshop intended for UK healthcare professionals which has been organised and funded by AstraZeneca.
Ondexxya® has conditional approval for adult patients treated with apixaban or rivaroxaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Great Britain Prescribing Information
Northern Ireland Prescribing Information
|
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033 |
